1. Home
  2. AXGN vs TRVI Comparison

AXGN vs TRVI Comparison

Compare AXGN & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Axogen Inc.

AXGN

Axogen Inc.

HOLD

Current Price

$35.98

Market Cap

2.6B

Sector

Health Care

ML Signal

HOLD

Logo Trevi Therapeutics Inc.

TRVI

Trevi Therapeutics Inc.

SELL

Current Price

$12.38

Market Cap

2.6B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
AXGN
TRVI
Founded
N/A
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.6B
2.6B
IPO Year
2013
2019

Fundamental Metrics

Financial Performance
Metric
AXGN
TRVI
Price
$35.98
$12.38
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
12
11
Target Price
★ $53.67
$28.18
AVG Volume (30 Days)
1.3M
★ 2.4M
Earning Date
10-28-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 31.91
EPS
N/A
★ N/A
Revenue
★ $225,208,000.00
N/A
Revenue This Year
$26.82
N/A
Revenue Next Year
$28.63
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 20.21
N/A
52 Week Low
$16.24
$9.82
52 Week High
$52.91
$20.22

Technical Indicators

Market Signals
Indicator
AXGN
TRVI
Relative Strength Index (RSI) 30.22 23.28
Support Level $30.29 $10.13
Resistance Level $44.83 $13.55
Average True Range (ATR) 1.47 0.63
MACD -0.36 -0.06
Stochastic Oscillator 12.34 9.07

Price Performance

Historical Comparison
AXGN
TRVI

About AXGN Axogen Inc.

Axogen Inc is engaged in the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. The company provides clinically and economically effective repair solutions for surgeons and health care providers. Its products include Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap, and Avive Soft Tissue Membrane. It also offers an Axotouch Two-Point Discriminator used to measure the innervation density of any surface area of the skin. Its products are available in the United States, Canada, Germany, the United Kingdom, Spain, and several other countries.

About TRVI Trevi Therapeutics Inc.

Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.

Share on Social Networks: